Skip to main content
. 2017 Jun 7;8:15699. doi: 10.1038/ncomms15699

Figure 7. VEGFR1 is epistatic to Rab27a.

Figure 7

(a,b) (a) HUVEC angiogenic sprouts and (b) quantification of sprouting after indicated treatments, scale bar: 200 μm. (sprouts per bead, No. of beads: ntRNA=18; siRab27a=15; siVEGFR1=16); three replicates. (c) Immunoblot of HUVEC with indicated treatments; three replicates. (d–g) (d) HUVEC angiogenic sprouts with indicated treatments, scale bar: 200 μm. FC, control; R1-FC, recombinant human VEGFR1. (e) Quantification of sprouts per bead. (f) pERK immunofluorescence of HUVEC angiogenic sprouts with indicated treatments, scale bar: 20 μm. (g) pERK quantification via integrated density. (pERK fluorescence, No. of sprouts: ntRNA/FC=8; ntRNA/R1-FC=9; siRab27a/FC=10; siRab27a/R1-FC=7; sprouts per bead, No. of beads: ntRNA/FC=14; ntRNA/R1-FC=14; siRab27a/FC=12; siRab27a/R1-FC=15); three replicates. (h,i) (h) pVEGFR2 (Y1175) Immunofluorescence of HUVEC angiogenic sprouts with indicated treatments, scale bar: 10 μm. (i) pVEGFR2 quantification via integrated density. (No. of sprouts: ntRNA=9; siRab27a=9); three replicates. Statistics: Shown are means +95% CI. One-way ANOVA and pairwise comparison with post-hoc Tukey's range test. *P≤0.05; **P≤0.01.